Quinn L Deveraux

USPTO Granted Patents = 38 (Patent Applications = 17)

CIPO Patents = 6 (Patent Applications = 8)

EPO Patents = 7 (Patent Applications = 6)

Average Co-Inventor Count = 5.3

ph-index = 8

Forward Citations = 186(Granted Patents)

Location History:

San Diego, CA (US) (2001 - 2022)
La Jolla, CA (US) (2015 - 2024)

Company Filing History:

Inhibrx Biosciences, Inc.

patents

3 out of 99

Sanford-burnham Medical Research Institute

The Burnham Institute

patents

6. 2 out of 21

Elanco Tiergesundheit Ag

patents

7. 2 out of 54

Burnham Institute for Medical Research

patents

8. 1 out of 15,462

University of California

patents

where one patent can have more than one assignee

Years Active: 2001-2025

Loading Chart...

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12227584 - Multivalent and multispecific OX40-binding fusion proteins (2025-02-18),

2. 12195533 - Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same (2025-01-14),

3. 12187804 - Multivalent and multispecific 41BB-binding proteins (2025-01-07),

4. 11976126 - Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells (2024-05-07),

5. 11965017 - Serpin fusion polypeptides and methods of use thereof (2024-04-23),

6. 11866507 - Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same (2024-01-09),

7. 11827691 - Serpin fusion polypeptides and methods of use thereof (2023-11-28),

8. 11566078 - PDL1-binding proteins (2023-01-31),

9. 11319377 - Monoclonal antibodies and methods of use (2022-05-03),

10. 11117973 - Multivalent and multispecific DR5-binding fusion proteins and methods of treating neoplasms (2021-09-14),

11. 11117972 - Multivalent and multispecific OX40-binding fusion proteins (2021-09-14),

12. 11046752 - Serpin fusion polypeptides and methods of use thereof (2021-06-29),

13. 10844129 - Multivalent and multispecific glucocorticoid-induced TNFR-related protein (GITR)-binding single-domain antibody fusion proteins and encoding nucleic acids (2020-11-24),

14. 10745466 - Type III secretion system targeting molecules (2020-08-18),

15. 10730929 - Serpin fusion polypeptides and methods of use thereof (2020-08-04),

Title: Quinn L Deveraux: Innovator in Immunology and Therapeutics

Introduction: Quinn L Deveraux, based in San Diego, CA, is a renowned inventor with an impressive portfolio of 35 patents. His innovative work primarily focuses on developing molecules aimed at modulating immune responses and enhancing therapeutic applications.

Latest Patents: Among his latest contributions to the field, Deveraux has developed multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells. This invention specifically targets death receptor 5 (DR5), which plays a crucial role in immune cell regulation. Additionally, he has created serpin fusion polypeptides, which encompass various polypeptide sequences, including those derived from cytokines and serum albumin. These innovations have significant implications for therapeutic and diagnostic applications, showcasing his commitment to advancing medical science.

Career Highlights: Throughout his career, Quinn L Deveraux has made substantial contributions to immunology and therapeutic development. His professional journey includes significant tenures at esteemed organizations such as Inhibrx, Inc. and the Sanford-Burnham Medical Research Institute. His work at these institutions has allowed him to innovate and develop groundbreaking technologies that have the potential to transform treatment modalities.

Collaborations: Deveraux has collaborated with several notable colleagues in his field, including Brendan P Eckelman and John C Timmer. These partnerships have enabled him to enhance his research and leverage diverse expertise in his innovative endeavors.

Conclusion: Quinn L Deveraux represents a pioneering force in the realm of immunology and therapeutic invention. With 35 patents to his name and notable collaborations, his work continues to drive advancements that hold promise for medical science. Through his innovative spirit and dedication, he paves the way for future discoveries in immunotherapy and beyond.

This text is generated by artificial intelligence and may not be accurate.